RESUMEN

As a part of the efforts to quickly develop pharmaceutical treatments for COVID-19 through repurposing existing drugs, some researchers around the world have combined the recently released crystal structure of SARS-CoV-2 Mpro in complex with a covalently bonded inhibitor with virtual screening procedures employing molecular docking approaches. In this context, protease inhibitors (PIs) clinically available and currently used to treat infectious diseases, particularly viral ones, are relevant sources of promising drug candidates to inhibit the SARS-CoV-2 Mpro, a key viral enzyme involved in crucial events during its life cycle. In the present perspective, we summarized the published studies showing the promising use of HIV and HCV PIs as potential repurposing drugs against the SARS-CoV-2 Mpro.

Asunto(s)

Antivirales/farmacología , Tratamiento Farmacológico de COVID-19 , Proteínas M de Coronavirus/antagonistas & inhibidores , Reposicionamiento de Medicamentos , Inhibidores de Proteasas/farmacología , SARS-CoV-2/efectos de los fármacos , Antivirales/química , Sitios de Unión , COVID-19/virología , Proteínas M de Coronavirus/química , Proteínas M de Coronavirus/genética , Proteínas M de Coronavirus/metabolismo , Humanos , Cinética , Modelos Moleculares , Terapia Molecular Dirigida , Inhibidores de Proteasas/química , Unión Proteica , Conformación Proteica en Hélice alfa , Conformación Proteica en Lámina beta , Dominios y Motivos de Interacción de Proteínas , Ensayos Clínicos Controlados Aleatorios como Asunto , SARS-CoV-2/enzimología , SARS-CoV-2/genética , Termodinámica